Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024

Estrella Immunopharma, Inc.

EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.
IIS study: 6/12 CR (50%), 4/12 PR (33%), ORR 83%; no severe CRS; durable responses up to 23.2 months.
Partnered with Imugene (ASX:IMU) to combine CF33-CD19t oncolytic virus with EB103 for solid tumors.
Pipeline includes EB104 (CD19/CD22 dual-targeting) for lymphoma and EB201 for SLE (preclinical).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.